© 2022 MJH Life Sciences™ and Managed Healthcare Executive. All rights reserved.
Eyecare
A Blood Test May Help Identify Those at Risk for Diabetic Retinopathy
June 10, 2022
A biomarker used in kidney disease screening has potential to identify people with sight-threatening diabetic retinopathy.
Clinical Trials Show Positive Results for Novel Therapy for Dry Eye Disease
June 09, 2022
Perfluorohexyloctane prevents excessive tear evaporation and has the ability to restores tear film balance. A new drug application is expected to be filed this year.
Therapy for Age-Related Blurry Vision Shows Positive Results
May 31, 2022
If approved, Orasis’ low-dose pilocarpine would be the second product that improves presbyopia, which is the age-related loss of clear up-close vision. The company plans to submit an NDA in the second half of the year.
Nancy Lurker of EyePoint Pharmaceuticals Addresses Innovations in Eye Care, How to Grow in the C-Suite and What it Takes to Run a Biopharma Company
April 27, 2022
Briana Contreras, editor of Managed Healthcare Executive, spoke with Nancy Lurker, CEO and president of EyePoint Pharmaceuticals. Nancy shared a bit about EyePoint and how the organization’s innovative therapies are addressing patient needs through eye care, and most importantly, she addressed C-Suite positions like the CEO role. Nancy shared advice for those seeking to reach the CEO level, especially toward women in healthcare and other roles, and what it takes to run a biopharma company.
Five Tips to Help Block Blue Light in an Increasingly Remote World
January 16, 2022
The use of digital devices has surged significantly as people spend more time at home, with Americans logging an average of 13 hours per day watching screens. That compares to between seven and 10 hours per day before the COVID-19 pandemic started, with the increase in screen time likely contributing to more exposure to blue light.
Ophthalmologist Group Wants U.S. Government to Push Back Against Avastin Biosimilars
August 09, 2021
The American Academy of Ophthalmology says biosimilar alternatives to Avastin have never been tested in the eye.
Future of Wet AMD Treatment
July 21, 2021
Diana Do, MD, and Steven Peskin, MD, MBA, FACP, discuss unmet needs and future approaches to treatment in wet AMD.
Managed Care Considerations in Wet AMD
July 21, 2021
Steven Peskin, MD, MBA, FACP, provides insight into managed care considerations of wet AMD including clinical evidence evaluation, formulary management, and value-based agreements.
Clinical Trial Evidence and Outcomes in Wet AMD
July 21, 2021
Diana Do, MD, discusses outcomes of interest for anti-VEGF agents, clinical evidence supporting the treat-and-extend approach, and strategies to overcome financial barriers in wet AMD.
Treatment Selection in Wet AMD
July 21, 2021
Diana Do, MD, provides insight into anti-VEGF treatment selection for individual patients, evaluation of patient response to therapy, and considerations for switching of agents.